Can I legally buy corticotropin online and import it into the EU?

No. Importing corticotropin from outside the EU is illegal, even with a prescription. Customs agencies routinely seize unauthorised medications. The only legal access is through approved EMA-authorised therapies available via healthcare providers.

Is there an EMA-approved version of corticotropin or ACTH?

No EMA-approved corticotropin product exists. However, ACTH-analogues and other related compounds may be available in some EU countries. Ask your doctor about approved alternatives for your specific condition.

Why is corticotropin approved in the US but not the EU?

The manufacturer has not submitted it for EMA approval, likely due to commercial considerations. The EU's stricter pricing regulation and preference for evidence-based alternatives to oral steroids make the market less attractive.

Can my doctor prescribe corticotropin off-label in the EU?

No. Off-label prescribing applies only to approved medicines. Since corticotropin is not EMA-authorised, doctors cannot legally prescribe it, even off-label.

What should I do if corticotropin was mentioned as a treatment option?

Discuss approved alternatives with your healthcare provider. Many conditions treated with corticotropin in the US have established European protocols using other therapies. Clinical trials may also be available in your area.

Corticotropin Legal Status in the EU: What You Need to Know

Corticotropin—the ACTH-based injectable hormone therapy sold as Acthar Gel in the US—is not authorised by the European Medicines Agency (EMA). This means it is not licensed for prescription or sale anywhere in the European Union, regardless of country. Unlike the US, where it carries FDA approval for 19 conditions including infantile spasms and multiple sclerosis relapses, European patients and clinicians cannot legally access it through standard medical channels. The absence of EMA authorisation reflects both commercial decisions and the regulatory framework that governs pharmaceutical approval across EU member states.

Why Corticotropin Isn't Available in the EU

Corticotropin has never been submitted for or granted EMA marketing authorisation. The EMA's centralised procedure is the gateway for any medication to be legally marketed across EU member states. Without it, corticotropin cannot be prescribed, dispensed, or legally imported for medical use.

This differs markedly from the US situation. The FDA approved corticotropin (as Acthar Gel, manufactured by Mallinckrodt) in 1952, and it has remained on the market ever since—though its commercial trajectory has been turbulent. The drug carries approximately 19 FDA-approved indications, making it one of the few ACTH products with formal regulatory blessing in a major market. The EU's absence of approval suggests either:

Commercial prioritisation: The manufacturer may not have found sufficient market incentive to pursue EMA licensing, given smaller patient populations and stricter price regulation in Europe.
Regulatory strategy: Some drug companies focus resources on the US market first, where pricing power is higher and approval timelines can be faster.
Clinical evidence thresholds: European regulators may have applied different evidentiary standards to historical approval data, particularly for older compounds.

EMA Regulatory Framework for Corticotropin

European pharmaceutical regulation operates through the centralised procedure, which evaluates drugs against criteria including:

Quality: Manufacturing standards and chemical consistency
Safety: Toxicology, adverse event profiles, and risk management
Efficacy: Clinical trial data demonstrating benefit in stated indications

For a hormone-based therapeutic like corticotropin, the EMA would expect robust evidence that ACTH therapy offers clear advantages over existing alternatives. In the EU, oral corticosteroids (like prednisolone) are widely used and well-established for many of the conditions where corticotropin carries US approval. Demonstrating superiority—rather than non-inferiority—would likely be required.

Notably, infantile spasms (West syndrome), where corticotropin is a first-line therapy in the US, is also treated in the EU using other agents. Vigabatrin and other anti-seizure medications form the backbone of European treatment protocols. While some European clinicians may believe ACTH has immunomodulatory advantages beyond standard steroids, this hasn't translated into a formal regulatory application or approval.

What "Not Authorised by the EMA" Means Legally

When a compound is "not authorised by the EMA," the legal implications are clear and binding:

For patients: Corticotropin cannot be legally prescribed or dispensed by hospitals, clinics, or pharmacies in any EU member state. It is not available through the standard healthcare system or private prescriptions.

For healthcare providers: Doctors cannot legally prescribe it, even off-label, because there is no legal supply chain. Off-label use of approved drugs is permitted in the EU; off-label use of unauthorised drugs is not.

For importation: Private importation of corticotropin for personal use is illegal in most EU jurisdictions. Even if purchased from a non-EU supplier, it cannot legally enter the EU for medical purposes.

For research: Clinical trials using corticotropin require investigational medicinal product (IMP) authorisation from national regulatory authorities, a different pathway from commercial approval.

The US-EU Approval Divide

Corticotropin exemplifies a broader pattern: many older, niche therapeutics are approved in the US but not the EU. The reasons vary, but key differences in regulatory philosophy matter:

Historical data acceptance: The FDA has been more willing to rely on legacy clinical evidence and physician experience for compounds approved decades ago. The EMA, established in 1995, applies more modern evidentiary standards.
Commercial pricing: The EU's price-regulation frameworks and health technology assessment requirements make it less attractive for high-cost drugs. Acthar Gel's price—which reportedly exceeded $38,000 per vial in the US—would face intense scrutiny in European health systems.
Therapeutic alternatives: The EU may view existing, cheaper oral corticosteroids as adequate substitutes, reducing incentive for companies to pursue approval of a more expensive injectable ACTH product.

For corticotropin specifically, no evidence suggests the EMA has rejected an application. Rather, no application appears to have been submitted. This is a commercial decision, not a regulatory one.

Regulatory History and Timeline

Corticotropin has a long clinical history:

1950s: ACTH extracts isolated from animal pituitary glands; used empirically for autoimmune conditions
1952: FDA approval granted (one of the earliest biologics approved)
1970s–1990s: Continued US use, particularly in infantile spasms and multiple sclerosis
2010 onwards: Acthar Gel became a high-profile commercial story due to price escalation following acquisition by Mallinckrodt
Present: No EMA submission on record; not available in EU

Within the EU, national regulatory pathways exist for individual member states, but they are subordinate to EMA authorisation for cross-border distribution. Some EU countries permit compassionate use or named-patient programs for unauthorised drugs in exceptional circumstances, but this requires case-by-case approval and is not a standard pathway.

What This Means for European Patients

If you or a family member in the EU has a condition for which corticotropin is used in the US—such as infantile spasms, multiple sclerosis relapses, or nephrotic syndrome—here's what you should know:

Standard treatment options are available: European healthcare systems have established, evidence-based protocols for these conditions using approved medications. These may include alternative ACTH-like compounds, oral corticosteroids, or immunosuppressants.

Clinical trials may be an option: If a trial involving corticotropin or related compounds is recruiting in your country, participation may provide access alongside rigorous monitoring. Check ClinicalTrials.gov and your country's national trial registry.

Off-label alternatives exist: Doctors can prescribe approved drugs off-label for conditions outside their labelled indication. While they cannot prescribe corticotropin itself, they may use alternatives with similar pharmacology that are EMA-approved.

Cross-border access is not legal: Importing corticotropin from the US or other non-EU countries for personal medical use is illegal, regardless of whether you have a prescription. Enforcement varies, but customs agencies can seize unauthorised medications.

Enforcement and Penalties

EU member states enforce pharmaceutical regulations through national competent authorities. Violations—such as importing or selling unauthorised corticotropin—can result in:

Seizure of the product at customs or pharmacy level
Fines for individuals or healthcare providers
Criminal charges in cases of intentional trafficking
Loss of medical licensing for practitioners who prescribe it

The severity depends on the member state and intent. A patient attempting to import a small quantity for personal use typically faces confiscation rather than prosecution. However, a healthcare provider prescribing it knowingly would face serious professional and legal consequences.

Could Corticotropin Be Approved in the EU in the Future?

Theoretically, yes—but prospects are limited. For approval to occur, a sponsor (likely Mallinckrodt or a licensee) would need to:

Submit a Marketing Authorization Application (MAA) through the centralised procedure
Provide comprehensive safety and efficacy data meeting EMA standards
Address pricing and health economic questions
Demonstrate added benefit over existing therapies

Given the drug's age, the availability of alternatives, and the commercial barriers in the EU market, a new application seems unlikely. If anything, a generic or biosimilar ACTH product might be more attractive commercially, but even this remains speculative.

Key Takeaways

Corticotropin is not legal in the EU because it is not EMA-authorised. It cannot be prescribed, purchased, or legally imported. European patients requiring ACTH-like therapy have access to alternative treatments that are formally approved and integrated into healthcare protocols. If you are considering corticotropin or have been told it might help your condition, consult your European healthcare provider about approved alternatives—they are tested, regulated, and accessible through standard channels.

Corticotropin Legal Status in the EU: Regulatory Status & Access